Company Filing History:
1 out of 1,327 
1 out of 3,539 
Years Active: 2014
Title: Michael M Siedman: Innovator in Genetic Engineering
Introduction
Michael M Siedman is a notable inventor based in Washington, DC. He has made significant contributions to the field of genetic engineering, particularly through his innovative work on oligonucleotides. His research focuses on the development of high-affinity, chemically modified triplex-forming oligonucleotides (TFOs) that have the potential to revolutionize targeted mutagenesis.
Latest Patents
Siedman's most recent patent is titled "Modified triple-helix forming oligonucleotides for targeted mutagenesis." This patent describes TFOs that bind as third strands to duplex DNA in a sequence-specific manner. The oligonucleotides can be composed of various combinations of nucleotides and modified nucleotides, which may include chemical modifications of the heterocyclic base, sugar moiety, or phosphate moiety. The invention emphasizes the generation of a high-affinity oligonucleotide with a binding constant (K) of less than 2×10, which forms a triple strand with a specific DNA segment of a target gene. This binding stimulates mutations within or adjacent to the target region, thereby activating, inactivating, or altering the function of the target gene.
Career Highlights
Throughout his career, Siedman has worked with prestigious institutions, including Yale University and the National Institutes of Health, which is a component of the US Department of Health & Human Services. His work has been instrumental in advancing the understanding of genetic manipulation and its applications in various fields.
Collaborations
One of his notable collaborators is Peter M Glazer, with whom he has worked on various projects related to genetic engineering and oligonucleotide research.
Conclusion
Michael M Siedman's contributions to the field of genetic engineering through his innovative patents and collaborations highlight his role as a leading inventor in this area. His work continues to influence advancements in targeted mutagenesis and genetic research.